Acotiamide HydrochlorideHydrate/Acofide®
Basic Information
Acotamine hydrochloride was jointly developed by Japan Zeria and Astellas. It was approved by the Japanese Pharmaceutical Medical Device Integration Agency (PMDA) on March 25, 2013, and was jointly produced by Zeria and Anstel. It is marketed in Japan under the trade name Acofide®.
Acotamine hydrochloride is a novel selective acetylcholinesterase (AChE) inhibitor. Acetylcholine is an important neurotransmitter that regulates gastrointestinal motility. Acotamine improves the symptoms of functional dyspepsia by inhibiting the degradation of acetylcholine, improving impaired gastric motility and delayed gastric emptying. This medicine is suitable for improving the feeling of postprandial bloating caused by functional dyspepsia, feeling of fullness in the upper abdomen and premature sensation.
Acofide® is an oral film-coated tablet containing 100 mg of acotamine hydrochloride. The recommended dose is 100 mg per adult, 3 times a day, before meals.
Structural formula
Mechanism
synthetic route
Research key data
This article is transferred from：https://news.pharmacodia.com/news/html/info/info-detail.html?id=29421
